Revised therapeutic window for vancomycin in pediatric patients: evidence from a retrospective therapeutic drug monitoring study

Abstract Objective Methicillin-resistant Staphylococcus aureus (MRSA) infections among children are escalating annually. Vancomycin serves as the frontline therapeutic agent against MRSA infections. However, determining the therapeutic window that maximizes efficacy while minimizing the risk of toxi...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Tao Zhang, Jingjing Yi, Hua Cheng, Xinyan Han, Yan Wang, Jiao Xie, Qianting Yang, Sasa Hu, Yalin Dong
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2025-11-01
סדרה:	BMC Pharmacology and Toxicology
נושאים:	Vancomycin Pediatrics Therapeutic drug monitoring Therapeutic window Pharmacodynamics
גישה מקוונת:	https://doi.org/10.1186/s40360-025-01035-6
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!